查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924701

依给药途径、药物类别、通路和最终用户分類的酒精使用障碍治疗市场－2026-2032年全球预测

Medications for Alcohol Use Disorder Market by Route of Administration, Drug Class, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，酒精使用障碍治疗市场价值将达到 11 亿美元，到 2026 年将成长到 12 亿美元，到 2032 年将达到 21.7 亿美元，复合年增长率为 10.11%。

关键市场统计数据
基准年 2025 11亿美元
预计年份：2026年 12亿美元
预测年份 2032 21.7亿美元
复合年增长率 (%) 10.11%

策略实施以不断发展的临床证据、製剂技术、支付方优先事项和实际差异为框架，这些因素共同塑造了酒精使用障碍的治疗方案。

酒精使用障碍的治疗正经历持续的变革时期，这主要受不断发展的临床证据、新型製剂技术以及支付者和监管机构优先事项转变的推动。本文概述了现代治疗格局，重点在于阐述了不同剂型和药物类别的治疗方案如何竞争临床应用，以及系统层面的压力如何优先考虑安全性、依从性和实际疗效。本文也着重介绍了不同给药平台（注射剂与口服片剂）之间的实际差异及其对临床工作流程、患者依从性模式和供应链的影响，从而为上述变革提供了背景资讯。

製剂创新、可操作证据的产生、监管审查以及支付方的价值需求如何重塑治疗方法的采纳和商业策略

近年来，临床研发、製剂科学和医疗保健系统行为的变革性变化正在重新定义酒精使用疾患治疗的评估和应用方式。缓释技术和注射的进步正在重塑关于依从性和长期復发预防的临床讨论，而口服缓释製剂的逐步改进则为偏好非侵入性治疗的患者提供了更多选择。同时，真实世界证据的产生和实用性临床试验正在影响处方实践，它们不仅在对照试验环境中，而且在日常临床实践中也提供了疗效比较数据。

2025 年关税环境及其对治疗药物采购、区域製造、供应连续性和商业性定价动态的策略影响

2025年实施的关税和贸易措施为酒精使用障碍药物的生产商和经销商在采购、供应链设计和定价策略方面带来了新的营运限制。新的关税制度提高了某些进口零件和成品的相对成本，迫使生产商重新评估其采购来源，并在条件允许的情况下加快生产本地化。这些变化正在影响企业的策略优先顺序，因为企业需要权衡集中式低成本生产和分散式生产之间的利弊，后者可以降低关税风险并缩短前置作业时间。

可操作的細項分析揭示了产品供应和药物类别特征如何影响临床应用、营运设计和商业性重点。

详细的細項分析揭示了不同产品类型和药物类别在临床、营运和商业性影响方面的显着差异，为产品组合和市场推广策略提供了参考。依产品类型划分，注射疗法需要肌肉注射基础设施，在某些情况下还需要静脉输注，这影响了其在住院戒毒病房和专科诊所的应用。另一方面，口服药片的依从性动态取决于其采用的是缓释技术还是速释技术。这些给药方式的差异不仅影响临床医师的偏好和病患选择，也影响物流、某些注射所需的低温运输以及安全给药的训练要求。

区域指导方针旨在协调监管差异、支付方成熟度和临床服务规范，从而优化全球医疗保健系统的可近性、报销和应用。

区域趋势对监管路径、支付方框架和采纳模式有着显着影响，从而在美洲、欧洲、中东和非洲以及亚太地区形成了各自独特的战略要务。在美洲，整合的医疗服务体系和与私人支付方强大的谈判能力为快速采纳基于价值的合约和循证药物配方创造了机会；然而，都市区和非洲的监管环境则呈现出多样性，各国不同的法规环境决策和国家处方笺流程可能会加速或延缓药物进入市场，此外，定价和卫生经济学的文件要求也十分复杂。

企业策略、生产伙伴关係和证据产生三者结合，决定了治疗药物供应和市场进入的竞争优势。

公司层面的趋势持续影响着创新轨迹和竞争定位，领导企业正寻求透过投资差异化给药技术、进行实证研究和相关人员来巩固其在治疗领域的主导。生物製药公司与合约研发生产机构（CDMO）之间的策略联盟正在推动缓释注射剂和缓释口服製剂平台的快速规模化生产，而与学术机构和医疗系统的合作则正在产生真实世界证据，为与支付方的谈判和指南的采纳提供依据。同时，规模较小的专业公司和新兴生物技术公司正专注于细分市场定位，开发标靶製剂，并寻求现有分子的适应症拓展，以填补尚未满足的临床需求。

实际的优先建议，整合了配方选择、证据产生、加强供应链和支付方合作，以促进产品应用并保持竞争优势。

产业领导者应优先考虑一系列切实可行的倡议，以协调临床、营运和商业性需求，加速合理应用，并保持竞争优势。首先，应投资于符合预期临床应用情境的製剂选择和给药系统，确保肌肉注射、静脉输注和口服缓释/速释片剂的选择能反映实际给药方案和病患偏好。其次，应将可靠的真实世界证据项目与务实的试验设计相结合，以展示能够引起支付方和临床医生共鸣的疗效比较、依从性优势和医疗资源利用结果。

结合有针对性的相关人员访谈、二手文献综述和情境分析，采用严谨的混合方法，为决策者提供可复製、可操作的见解。

本研究结合了对临床领导者、支付者和供应链专家的定性访谈，以及对同行评审文献、监管指南和公共趋势的二次分析，以确保对治疗格局形成多方面的观点。主要研究包括针对注射剂与口服疗法的临床驱动因素、肌肉注射和静脉输注环境的操作限制以及支付方对疗效和成本控制的期望等问题的结构化访谈。二次资讯用于分析不同药物类别（Acamprosate、Baclofen、Disulfiram崙、纳曲酮（长效注射剂和口服剂）和托吡酯）的安全讯号、药理特性和历史应用模式。

简洁扼要、全面全面的分析，重点在于阐述製剂创新、药物类别特征、支付方趋势和供应弹性等因素之间的相互作用，为策略决策提供基础。

总而言之，酒精使用障碍的治疗格局正在发生变化，这需要临床、营运和商业性方面的协调应对。製剂和给药方式的进步为提高患者依从性和长期治疗效果提供了切实的机会，但也带来了必须积极应对的物流和支付方相关复杂问题。不同药物类别的特性进一步增加了决策的复杂性。从用于维持治疗的药物到需要监督给药的药物，每种治疗方案都有其独特的推广驱动因素和证据要求。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依给药途径分類的酒精使用障碍治疗市场

  • 注射
    • 注射（肌肉注射）
    • 皮下注射
  • 口服锭剂

9. 依药物类别分類的酒精使用疾患治疗市场

  • Acamprosate
  • Baclofen
  • Disulfiram
  • 纳曲酮
  • 托吡酯

10. 按分销管道分類的酒精使用障碍治疗市场

  • 在线的
  • 离线

第十一章 酒精使用疾患治疗药物市场（依最终使用者划分）

  • 医院
  • 研究所
  • 成瘾诊所

12. 各地区酒精使用疾患治疗药物市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 酒精使用疾患治疗药物市场（依类别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国酒精使用疾患治疗药物市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

15. 美国酒精使用疾患治疗药物市场

第十六章：中国酒精使用疾患治疗药物市场

第十七章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Alkermes
  • Ambica Pharma
  • Amigoz Lifesciences
  • Care Formulation Labs Private Limited
  • Consern Pharma Limited
  • Dhritee Impex
  • Eisai Pharmaceuticals India Pvt Ltd
  • Intas Pharmaceuticals Ltd.
  • Johnlee Pharmaceuticals Pvt. Ltd.
  • Lifegenix（Div. of Lifecare Neuro Products Ltd.）
  • Mallinckrodt Pharmaceuticals
  • Marshall Healthcare
  • Odyssey Pharmaceuticals
  • Rusan Pharma
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sanofi SA
  • Schwitz Biotech
  • Sun Pharmaceutical Industries Ltd.
  • Taj Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-7A380DA7C438

The Medications for Alcohol Use Disorder Market was valued at USD 1.10 billion in 2025 and is projected to grow to USD 1.20 billion in 2026, with a CAGR of 10.11%, reaching USD 2.17 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.10 billion
Estimated Year [2026] USD 1.20 billion
Forecast Year [2032] USD 2.17 billion
CAGR (%) 10.11%

A strategic introduction framing evolving clinical evidence, formulation technologies, payer priorities, and practical distinctions shaping treatment choices for alcohol use disorder

The treatment of alcohol use disorder is undergoing a sustained period of change driven by evolving clinical evidence, new formulation technologies, and shifting payer and regulatory priorities. This introduction frames the contemporary landscape by highlighting how therapeutic options across delivery formats and drug classes are competing for clinical adoption while system-level pressures prioritize safety, adherence, and real-world effectiveness. It sets the stage by clarifying the practical distinctions between delivery platforms-injectables versus oral tablets-and how those distinctions influence clinical workflows, patient adherence patterns, and supply chain considerations.

Furthermore, the introduction unpacks how an expanded therapeutic toolkit now includes multiple pharmacological classes with different mechanisms of action and administration requirements, prompting clinicians and health systems to adopt more nuanced treatment pathways. Given this complexity, stakeholders increasingly seek evidence that aligns formulation attributes, such as extended release injectables or immediate release oral tablets, with outcomes like retention in treatment and reductions in heavy drinking days. This context underscores the imperative for cross-functional strategies that account for clinical efficacy, administration modality, and payer acceptance to accelerate appropriate uptake and improve patient outcomes.

How innovations in formulation, pragmatic evidence generation, regulatory scrutiny, and payer value demands are reshaping therapeutic adoption and commercial strategy

Recent transformative shifts across clinical development, formulation science, and health system behavior are redefining how medications for alcohol use disorder are evaluated and adopted. Advances in extended release technologies and depot injectables have reoriented clinical conversations about adherence and long-term relapse prevention, while incremental improvements in oral extended release formulations have strengthened options for patients who prefer noninvasive therapies. At the same time, real-world evidence generation and pragmatic trials are influencing prescribing practices by providing data on comparative effectiveness in routine care settings rather than solely in controlled trials.

Concurrently, regulatory pathways and post-marketing surveillance have tightened expectations for safety monitoring and patient-reported outcomes, which is steering manufacturers toward robust pharmacovigilance frameworks and label expansions predicated on pragmatic endpoints. Payers and integrated delivery networks are increasingly focused on value-based contracting and outcomes-linked reimbursement, prompting manufacturers to demonstrate meaningful improvements in adherence, reductions in health-care utilization, and sustained abstinence or reduced heavy drinking. Taken together, these changes are prompting a reconfiguration of commercial strategies, with manufacturers investing in differentiated delivery formats, evidence generation partnerships, and stakeholder engagement to secure formulary placement and clinician buy-in.

The 2025 tariff environment and its strategic implications for sourcing, regional manufacturing, supply continuity, and commercial pricing dynamics across therapeutic formulations

The imposition of tariffs and trade measures in 2025 has introduced new operational constraints that reverberate across procurement, supply-chain design, and pricing strategy for manufacturers and distributors of medications for alcohol use disorder. Emerging tariff regimes have raised the relative cost of certain imported components and finished formulations, prompting manufacturers to reassess sourcing decisions and to accelerate regional manufacturing localization where feasible. These shifts are influencing strategic prioritization, as companies evaluate the trade-offs between centralized, low-cost production and decentralized manufacturing that mitigates tariff exposure and shortens lead times.

In response, supply-chain teams have increased focus on nearshoring, inventory buffering, and multi-sourcing critical active pharmaceutical ingredients and finished dose forms for both injectable platforms and oral tablets. These operational adjustments aim to preserve continuity of supply for intramuscular injection and intravenous infusion products as well as for extended release and immediate release oral formulations. Additionally, commercial teams must recalibrate pricing and contracting approaches to maintain market access amid added cost pressures while preserving affordability for patients and payers. Ultimately, the tariff environment has accelerated strategic planning cycles, compelling stakeholders to integrate trade policy scenarios into clinical development and commercialization roadmaps.

Actionable segmentation insights revealing how product delivery formats and distinct drug-class characteristics drive clinical adoption, operational design, and commercial focus

Deep segmentation analysis reveals meaningful differences in clinical, operational, and commercial implications across product types and drug classes that should inform portfolio and go-to-market decisions. By product type, injectable therapies require infrastructure for intramuscular injection and, in some settings, intravenous infusion, which influences adoption in inpatient detoxification units and specialized clinics, while oral tablets present differing adherence dynamics depending on whether they utilize extended release or immediate release technologies. These modality distinctions affect not only clinician preference and patient selection but also logistics, cold-chain needs for certain injectables, and training requirements for safe administration.

By drug class, therapeutic choice carries implications for mechanism-driven efficacy and tolerability profiles that shape prescriber behavior and patient trajectories. Acamprosate and baclofen are often positioned for maintenance strategies with attention to long-term tolerability, whereas disulfiram continues to occupy a niche where supervised administration and behavioral supports are central to effectiveness. Naltrexone presents a bifurcated pathway, as both extended release injectable formulations and oral tablets are in clinical use, each offering trade-offs between adherence assurance and ease of discontinuation or dose adjustment. Topiramate, used off-label in many jurisdictions, requires careful titration and monitoring for cognitive side effects. Taken together, these segmentation dimensions suggest that successful commercialization requires synchronized strategies that align formulation attributes with drug-class specific clinical profiles and the operational realities of intended care settings.

A regional playbook that aligns regulatory variation, payer maturity, and clinical delivery norms to optimize access, reimbursement, and adoption across global health systems

Regional dynamics exert pronounced influence on regulatory pathways, payer frameworks, and adoption patterns, producing distinct strategic imperatives across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated delivery systems and a high degree of private payer negotiation create opportunities for value-based contracting and rapid uptake of evidence-backed formulations, although access disparities persist between urban centers and rural areas. In contrast, Europe, Middle East & Africa features heterogeneous regulatory environments where country-level reimbursement decisions and national formulary processes can either accelerate or slow market entry, requiring nuanced pricing and health-economic dossiers.

Meanwhile, Asia-Pacific presents a mix of rapidly expanding health-care infrastructure and diverse payer maturity, which supports multiple commercialization models from hospital-based specialty distribution for injectables to pharmacy-driven supply for oral tablets. Each region also carries distinct clinical practice patterns; for example, some countries prioritize supervised administration programs that may favor depot injectables, while others emphasize outpatient management where oral immediate release or extended release tablets are more practical. Consequently, regional strategies must reconcile regulatory timing, procurement logistics, and clinical delivery norms to optimize access, reimbursement, and long-term uptake across disparate health systems.

How corporate strategy, manufacturing partnerships, and evidence generation are converging to determine competitive advantage in therapeutic delivery and market access

Company-level dynamics continue to shape innovation trajectories and competitive positioning, with leaders investing in differentiated delivery technologies, evidence generation, and stakeholder engagement to secure therapeutic leadership. Strategic partnerships between biopharma companies and contract development and manufacturing organizations are enabling rapid scale-up of depot injectables and extended release oral platforms, while alliances with academic centers and health systems are producing real-world evidence that informs payer negotiations and guideline inclusion. At the same time, smaller specialty firms and emerging biotech companies focus on niche positioning, developing targeted formulations or pursuing label expansions for established molecules to capture unmet clinical segments.

Commercially, firms that integrate lifecycle planning-from early formulation selection to post-marketing safety programs and value demonstration-are better positioned to navigate complex reimbursement landscapes. Investment in clinician education, nurse-led administration pathways, and digital adherence tools can differentiate products in crowded therapeutic classes. Moreover, companies that proactively address manufacturing resilience and tariff-related supply-chain risks secure a competitive advantage by ensuring consistent product availability, which translates directly into prescriber confidence and patient continuity of care.

Practical and prioritized recommendations that synchronize formulation selection, evidence generation, supply resilience, and payer engagement to accelerate adoption and sustain competitive differentiation

Industry leaders should prioritize a set of actionable initiatives that align clinical, operational, and commercial imperatives to accelerate appropriate use and sustain competitive advantage. First, invest in formulation choices and delivery systems that match intended care settings, ensuring that choices between intramuscular injection, intravenous infusion, and oral extended or immediate release tablets reflect real-world administration capacity and patient preferences. Next, integrate robust real-world evidence programs and pragmatic trial designs to demonstrate comparative effectiveness, adherence benefits, and health-care utilization outcomes that resonate with payers and clinicians.

Simultaneously, reassess supply-chain architectures to mitigate tariff exposure through multi-sourcing strategies and regional manufacturing where feasible, and enhance manufacturing transparency to support procurement negotiations. From a commercial standpoint, develop modular value propositions tailored to different drug classes, emphasizing tolerability profiles and mechanism of action where relevant. Strengthen provider education and training for safe administration of injectables and create digital tools to support adherence for oral regimens. Finally, pursue strategic payer engagements early to explore outcomes-based contracting or pilot programs that align incentives around patient-centered outcomes and long-term treatment retention.

A rigorous mixed-methods approach combining targeted stakeholder interviews, secondary literature integration, and scenario analysis to produce reproducible, actionable insights for decision-makers

This research synthesizes primary qualitative interviews with clinical leaders, payers, and supply-chain experts alongside secondary analysis of peer-reviewed literature, regulatory guidance, and public policy developments to ensure a multidimensional view of the therapeutic landscape. Primary engagement included structured interviews that probed clinical decision drivers for injectable versus oral therapies, operational constraints for intramuscular injection and intravenous infusion settings, and payer expectations for outcomes and cost containment. Secondary sources were leveraged to contextualize safety signals, pharmacology, and historical adoption patterns across drug classes including acamprosate, baclofen, disulfiram, naltrexone in both extended release injectable and oral forms, and topiramate.

Analytical techniques combined thematic qualitative synthesis with scenario planning to assess the impact of regulatory shifts and tariff environments on supply-chain and pricing strategies. Where applicable, triangulation between stakeholder interviews and published clinical evidence was used to validate practice-pattern assertions and to identify gaps requiring further primary research. The approach prioritizes transparency in assumptions and emphasizes reproducibility of findings through clear documentation of data sources, interview guides, and analytic frameworks, enabling stakeholders to adapt the insights to their unique strategic questions.

A concise synthesis highlighting the interplay of formulation innovation, drug-class nuances, payer dynamics, and supply resilience necessary to inform strategic decision-making

In summary, the treatment landscape for alcohol use disorder is evolving in ways that require coordinated clinical, operational, and commercial responses. Advances in formulation and delivery modalities create real opportunities to improve adherence and long-term outcomes, but they also introduce logistical and payer-related complexities that must be proactively managed. Drug-class specific profiles further complicate the decision environment; each therapeutic option-from agents used for maintenance strategies to medications that require supervised administration-carries distinct adoption drivers and evidence needs.

To navigate this complexity successfully, stakeholders should align formulation strategy with care-delivery realities, invest in real-world evidence to support value arguments, and strengthen supply-chain resilience in the face of trade-policy shifts. Companies that integrate these priorities into cohesive lifecycle plans and engage early with payers and clinicians will be best positioned to translate scientific advances into sustained clinical and commercial impact. This conclusion underscores the imperative for deliberate strategy, rigorous evidence generation, and operational foresight to realize the full potential of medication-based approaches to alcohol use disorder treatment.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Medications for Alcohol Use Disorder Market, by Route of Administration

  • 8.1. Injectables
    • 8.1.1. Injectable Intramuscular
    • 8.1.2. Injectable Subcutaneous
  • 8.2. Oral Tablets

9. Medications for Alcohol Use Disorder Market, by Drug Class

  • 9.1. Acamprosate
  • 9.2. Baclofen
  • 9.3. Disulfiram
  • 9.4. Naltrexone
  • 9.5. Topiramate

10. Medications for Alcohol Use Disorder Market, by Distribution Channel

  • 10.1. Online
  • 10.2. Offline

11. Medications for Alcohol Use Disorder Market, by End User

  • 11.1. Hospitals
  • 11.2. Research Institutes
  • 11.3. Addiction Clinics

12. Medications for Alcohol Use Disorder Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Medications for Alcohol Use Disorder Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Medications for Alcohol Use Disorder Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Medications for Alcohol Use Disorder Market

16. China Medications for Alcohol Use Disorder Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Alkermes
  • 17.6. Ambica Pharma
  • 17.7. Amigoz Lifesciences
  • 17.8. Care Formulation Labs Private Limited
  • 17.9. Consern Pharma Limited
  • 17.10. Dhritee Impex
  • 17.11. Eisai Pharmaceuticals India Pvt Ltd
  • 17.12. Intas Pharmaceuticals Ltd.
  • 17.13. Johnlee Pharmaceuticals Pvt. Ltd.
  • 17.14. Lifegenix (Div. of Lifecare Neuro Products Ltd.)
  • 17.15. Mallinckrodt Pharmaceuticals
  • 17.16. Marshall Healthcare
  • 17.17. Odyssey Pharmaceuticals
  • 17.18. Rusan Pharma
  • 17.19. Salvavidas Pharmaceutical Pvt. Ltd.
  • 17.20. Sanofi S.A.
  • 17.21. Schwitz Biotech
  • 17.22. Sun Pharmaceutical Industries Ltd.
  • 17.23. Taj Pharmaceuticals
  • 17.24. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLE SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ORAL TABLETS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ACAMPROSATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY BACLOFEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISULFIRAM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY NALTREXONE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY TOPIRAMATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ADDICTION CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 51. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 52. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 53. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 54. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 55. AMERICAS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 58. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 59. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 60. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 61. NORTH AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 65. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 66. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. LATIN AMERICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE, MIDDLE EAST & AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 76. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 82. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 83. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 84. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 85. MIDDLE EAST MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 88. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 89. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. AFRICA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 102. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 103. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 104. ASEAN MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 107. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 108. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. GCC MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 114. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPEAN UNION MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 119. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 120. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. BRICS MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 125. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 126. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 127. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. G7 MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 131. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 132. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. NATO MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 138. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 139. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. UNITED STATES MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 143. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY INJECTABLES, 2018-2032 (USD MILLION)
  • TABLE 145. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 146. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. CHINA MEDICATIONS FOR ALCOHOL USE DISORDER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)